Baker AT, Abuwarwar MH, Poly L, Wilkins S, Fletcher AL (2021) Cancer- associated fibroblasts and T cells: From mechanisms to outcomes. J Immunol 206: 310–320. doi:10.4049/jimmunol.2001203
Barrett RL, Pure´ E (2020) Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife 9: e57243. doi:10.7554/ eLife.57243
Bates D, Ma¨ chler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models Usinglme4. J Stat Softw 67: 1–48. doi:10.18637/jss.v067.i01
Borst J, Ahrends T, Ba˛ bała N, Melief CJM, Kastenmüller W (2018) CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18: 635–647. doi:10.1038/s41577-018-0044-0
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio` A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, et al (2015) Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 10: e0130142. doi:10.1371/journal.pone.0130142
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376: 2415–2426. doi:10.1056/NEJMoa1613493
Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD (2018) TGF- β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun 9: 4692. doi:10.1038/s41467-018-06654-8
Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, et al (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33: 463–479.e10. doi:10.1016/ j.ccell.2018.01.011
Davie K, Janssens J, Koldere D, De Waegeneer M, Pech U, Kreft Ł, Aibar S, Makhzami S, Christiaens V, Bravo Gonza´lez-Blas C, et al (2018) A single- cell transcriptome atlas of the aging Drosophila brain. Cell 174: 982–998.e20. doi:10.1016/j.cell.2018.05.057
Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B, Foreman O, Bainbridge TW, Castiglioni A, et al (2020) Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov 10: 232–253. doi:10.1158/ 2159-8290.CD-19-0644
Dow LE, Nasr Z, Saborowski M, Ebbesen SH, Manchado E, Tasdemir N, Lee T, Pelletier J, Lowe SW (2014) Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS One 9: e95236. doi:10.1371/journal.pone.0095236
DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064–1072. doi:10.1038/nprot.2009.95
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, et al (2019) Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen- presenting cancer-associated fibroblasts. Cancer Discov 9: 1102–1123. doi:10.1158/2159-8290.CD-19-0094
Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R (2018) Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: Overcoming resistance to single-agent checkpoint blockade. Clin Transl Med 7: 32. doi:10.1186/s40169-018- 0210-9
Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22: 433–438. doi:10.1038/nm.4051
Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246–2259. doi:10.1172/JCI73639
Hara A, Kato K, Ishihara T, Kobayashi H, Asai N, Mii S, Shiraki Y, Miyai Y, Ando R, Mizutani Y, et al (2021) Meflin defines mesenchymal stem cells and/or their early progenitors with multilineage differentiation capacity. Genes Cells 26: 495–512. doi:10.1111/gtc.12855
Hara A, Kobayashi H, Asai N, Saito S, Higuchi T, Kato K, Okumura T, Bando YK, Takefuji M, Mizutani Y, et al (2019) Roles of the mesenchymal stromal/ stem cell marker meflin in cardiac tissue repair and the development of diastolic dysfunction. Circ Res 125: 414–430. doi:10.1161/ CIRCRESAHA.119.314806
Ho J, Tumkaya T, Aryal S, Choi H, Claridge-Chang A (2019) Moving beyond P values: Data analysis with estimation graphics. Nat Methods 16: 565–566. doi:10.1038/s41592-019-0470-3
House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, et al (2020) Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res 26: 487–504. doi:10.1158/1078-0432.CCR-19-1868
Ichihara R, Shiraki Y, Mizutani Y, Iida T, Miyai Y, Esaki N, Kato A, Mii S, Ando R, Hayashi M, et al (2022) Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Pathol Int doi:10.1111/pin.13198Online ahead of print.
Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, et al (2020) CD4+ T-cell immunity in the peripheral blood correlates with response to anti- PD-1 therapy. Cancer Immunol Res 8: 334–344. doi:10.1158/2326- 6066.CIR-19-0574
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16: 582–598. doi:10.1038/nrc.2016.73
Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A, et al (2020) Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov 10: 1330–1351. doi:10.1158/2159- 8290.CD-19-1384
Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL (2019) Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 16: 282–295. doi:10.1038/s41575-019-0115-0
Kobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, Lida T, Ando R, Suzuki N, Lannagan TRM, et al (2021) The balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology 160: 1224–1239.e30. doi:10.1053/ j.gastro.2020.11.011
Kreiter S, Vormehr M, van de Roemer N, Diken M, Lo¨ wer M, Diekmann J, Boegel S, Schro¨ rs B, Vascotto F, Castle JC, et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692–696. doi:10.1038/nature14426
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al (2020b) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21: 1346–1358. doi:10.1038/s41590-020-0769-3
Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, et al (2020a) An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity 53: 187–203.e8. doi:10.1016/j.immuni.2020.06.016
Kuznetsova A, Brockhoff PB, Christensen RHB (2017) lmerTest package: Tests in linear mixed effects models. J Stat Softw 82: 1–26. doi:10.18637/ jss.v082.i13
Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwe´ H, Pircher A, Van den Eynde K, et al (2018) Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med 24: 1277–1289. doi:10.1038/s41591-018-0096-5
Le T, Phan T, Pham M, Tran D, Lam L, Nguyen T, Truong T, Vuong H, Luu T, Phung N, et al (2020) BBrowser: Making single-cell data easily accessible. BioRxiv doi:10.1101/2020.12.11.414136Preprint posted December 11, 2020.
Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al (2014) Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A 111: E3091–E3100. doi:10.1073/pnas.1411679111
Li S, Liu M, Do MH, Chou C, Stamatiades EG, Nixon BG, Shi W, Zhang X, Li P, Gao S, et al (2020) Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells. Nature 587: 121–125. doi:10.1038/s41586-020- 2850-3
Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W, Chou C, Do MH, Stamatiades EG, Gao S, et al (2020) TGF-β suppresses type 2 immunity to cancer. Nature 587: 115–120. doi:10.1038/s41586-020-2836-1
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, et al (2019) Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol 5: 1195–1204. doi:10.1001/jamaoncol.2019.1549
Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, Maruyama S, Ishikawa Y, Nishiyama T, Kiyoi H, et al (2016) Identification of meflin as a potential marker for mesenchymal stromal cells. Sci Rep 6: 22288. doi:10.1038/srep22288
Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M, et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369: 1481–1489. doi:10.1126/science.abc3421
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554: 544–548. doi:10.1038/nature25501
Matsumura Y (2020) Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv Drug Deliv Rev 154: 142–150. doi:10.1016/ j.addr.2020.07.003
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387–6392.
Miyai Y, Esaki N, Takahashi M, Enomoto A (2020) Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives. Cancer Sci 111: 1047–1057. doi:10.1111/cas.14346
Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, et al (2019) Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res 79: 5367–5381. doi:10.1158/0008-5472.CAN-19-0454
Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K, et al (2021) Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis. Eur Respir J 58: 2003397. doi:10.1183/13993003.03397-2020
O¨ hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214: 579–596. doi:10.1084/jem.20162024
O¨ zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25: 719–734. doi:10.1016/ j.ccr.2014.04.005
Piersma B, Hayward MK, Weaver VM (2020) Fibrosis and cancer: A strained relationship. Biochim Biophys Acta Rev Cancer 1873: 188356. doi:10.1016/j.bbcan.2020.188356
Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25: 735–747. doi:10.1016/j.ccr.2014.04.021
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124–128. doi:10.1126/science.aaa1348
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lo¨ wer M, Bukur V, Tadmor AD, Luxemburger U, Schro¨ rs B, et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547: 222–226. doi:10.1038/nature23003
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al (2017) iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18: e143–e152. doi:10.1016/S1470-2045(17)30074-8
Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: Meta-analysis. BMJ 362: K3529. doi:10.1136/bmj.k3529
Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159: 80–93. doi:10.1016/j.cell.2014.08.007
Shin K, Lim A, Zhao C, Sahoo D, Pan Y, Spiekerkoetter E, Liao JC, Beachy PA (2014) Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26: 521–533. doi:10.1016/j.ccell.2014.09.001
Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, Johnson ML, Markham MJ, Mileham KF, Beg MS, et al (2021) Clinical cancer advances 2021: ASCO[R8S2Q1M7]s report on progress against cancer. J Clin Oncol 39: 1165–1184. doi:10.1200/JCO.20.03420
Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, Miyai Y, Asai N, Enomoto A (2021) Roles of the mesenchymal stromal/stem cell marker Meflin/Islr in cancer fibrosis. Front Cell Dev Biol 9: 749924. doi:10.3389/fcell.2021.749924
Taki T, Shiraki Y, Enomoto A, Weng L, Chen C, Asai N, Murakumo Y, Yokoi K, Takahashi M, Mii S (2020) CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling. Cancer Sci 111: 4616–4628. doi:10.1111/cas.14673
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J, et al (2019) Welcome to the tidyverse. J Open Source Softw 4: 1686. doi:10.21105/joss.01686
Xiao Z, Mayer AT, Nobashi TW, Gambhir SS (2020) ICOS is an indicator of T- cell-mediated response to cancer immunotherapy. Cancer Res 80: 3023–3032. doi:10.1158/0008-5472.CAN-19-3265
Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, et al (2018) Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128: 2104–2115. doi:10.1172/ JCI96582
Zuazo M, Arasanz H, Ferna´ndez-Hinojal G, Garc´ıa-Granda MJ, Gato M, Bocanegra A, Mart´ınez M, Herna´ndez B, Teijeira L, Morilla I, et al (2019) Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med 11: e10293. doi:10.15252/emmm.201910293
Zuazo M, Arasanz H, Bocanegra A, Fernandez G, Chocarro L, Vera R, Kochan G, Escors D (2020) Systemic CD4 immunity as a key contributor to PD-L1/ PD-1 blockade immunotherapy efficacy. Front Immunol 11: 3087. doi:10.3389/fimmu.2020.586907